KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Quest Diagnostics (DGX) EBITDA (2016 - 2025)

Quest Diagnostics' EBITDA history spans 17 years, with the latest figure at $386.0 million for Q4 2025.

  • For Q4 2025, EBITDA rose 6.93% year-over-year to $386.0 million; the TTM value through Dec 2025 reached $1.6 billion, up 15.6%, while the annual FY2025 figure was $1.6 billion, 15.6% up from the prior year.
  • EBITDA for Q4 2025 was $386.0 million at Quest Diagnostics, roughly flat from $386.0 million in the prior quarter.
  • Across five years, EBITDA topped out at $660.0 million in Q1 2021 and bottomed at $135.0 million in Q4 2022.
  • The 5-year median for EBITDA is $373.5 million (2024), against an average of $398.6 million.
  • The largest annual shift saw EBITDA skyrocketed 277.14% in 2021 before it tumbled 74.81% in 2022.
  • A 5-year view of EBITDA shows it stood at $536.0 million in 2021, then crashed by 74.81% to $135.0 million in 2022, then surged by 97.78% to $267.0 million in 2023, then skyrocketed by 35.21% to $361.0 million in 2024, then rose by 6.93% to $386.0 million in 2025.
  • Per Business Quant, the three most recent readings for DGX's EBITDA are $386.0 million (Q4 2025), $386.0 million (Q3 2025), and $438.0 million (Q2 2025).